FDA has issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol for its experimental pancreatic cancer drug, daraxonrasib, a RAS inhibitor.
FDA has issued warning letters to eight retailers for selling unauthorized tobacco products, including nicotine pouches and dissolvable tobacco products.
